Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Mar. 24 announced the initiation of a pivotal global Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $8.00 moved to $8.10 on last trade day and at the end of the day closed at $ 8.06. Company price to sales ratio in past twelve months was calculated as 32.93 and price to cash ratio as 6.33. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive weekly performance of 6.05 %.
Arena Pharmaceuticals (NASDAQ:ARNA) saw a significant decrease in short interest during the month of January. As of March 14th, there was short interest totalling 56,270,707 shares, a decrease of 3.1% from the February 28th total of 58,068,228 shares, Analyst Ratings News reports. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 3.28% in last trading session and ended the day on $6.30. ARNA return on equity ratio is recorded as -19.10% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yearly performance is-21.45%.
Nordion Inc. (NYSE:NDZ) announced after the close Friday that it agreed to be acquired by Sterigenics for $11.75 per share, or approximately $727 million. Nordion Inc (USA) (NYSE:NDZ) shares moved up 10.66% in last trading session and was closed at $11.52 while trading in range of $11.50 – $11.62 – Nordion Inc (USA) (NYSE:NDZ) year to date (YTD) performance is 35.69%.
Halcon Resources Corp (NYSE:HK) entered into the Seventh Amendment to Senior Revolving Credit Agreement by and among the Company, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders signatory thereto (the “Credit Facility”). Halcon Resources Corp (NYSE:HK) weekly performance is 13.05%. On last trading day company shares ended up $4.33. Halcon Resources Corp (NYSE:HK) distance from 50-day simple moving average (SMA50) is 16.24%. Analysts mean target price for the company is $5.04.